CN1943689A - A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method - Google Patents
A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method Download PDFInfo
- Publication number
- CN1943689A CN1943689A CN 200510105972 CN200510105972A CN1943689A CN 1943689 A CN1943689 A CN 1943689A CN 200510105972 CN200510105972 CN 200510105972 CN 200510105972 A CN200510105972 A CN 200510105972A CN 1943689 A CN1943689 A CN 1943689A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- weight
- herba
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 9
- 201000009240 nasopharyngitis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 7
- 244000080767 Areca catechu Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 29
- 239000008187 granular material Substances 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000019634 flavors Nutrition 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 240000001972 Gardenia jasminoides Species 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 235000014435 Mentha Nutrition 0.000 claims description 2
- 241001072983 Mentha Species 0.000 claims description 2
- 241001522129 Pinellia Species 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 3
- 235000006226 Areca catechu Nutrition 0.000 abstract 1
- 235000001405 Artemisia annua Nutrition 0.000 abstract 1
- 240000000011 Artemisia annua Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 21
- 241000282326 Felis catus Species 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000013641 positive control Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000000954 anitussive effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000003801 laryngeal nerve Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 210000001139 rectus abdominis Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960001012 codeine hydrochloride Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960003436 pentoxyverine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
This invention provides a Chinese traditional medicinal composition for treatment of wind-heat type common cold. The composition is prepared by using fructus forsythiae,fermented soybean,peppermint herb,fineleaf schizonepeta herb,astragalus root(stir-fried), Rdixb et rhei, sweet wormwood herb, common peony root, betelnutpalm seed, officinal magnolia bark, laikal skullcap root, Ternate pinelia tuber, Chinese thorowax root, liquorice according to certain processing technology. It has obvious curative effects in treating infant patients suffered from wind-heat type common cold. It also reveals preparing method.
Description
Technical field
The present invention relates to treat the drug regimen and the preparation method of cold cough, refer to the botanical herbs to be medicine of the anemopyretic cold made of raw material and preparation method thereof especially.
Background technology
Influenza is commonly encountered diseases, frequently-occurring disease clinically, also is the principal disease that threatens human health.Nosetiology confirms that the flu more than 90% is a viral infection, and western medicine effects such as use antibiotics are all undesirable, and therefore, using the treatment by Chinese herbs influenza is present research direction.The tradition traditional Chinese medical science thinks that flu is a kind of clinical feel disease, and wherein anemopyretic cold is particularly common, when having some inkling of a cold, adopt " cold-pungent and diaphoretic prescriptions " more, but flu increase the weight of to outside pathogenic factor in the exterior is arranged, in when interior-heat is arranged, often need give " expelling pathogenic factors from muscles for reducing heat " class Chinese medicine, but this type of Chinese patent medicine lacks extremely at present.Particularly to pediatric pharmaceuticals, clinical practice still less.
The purpose of this invention is to provide a kind of quick-acting, Chinese medicine oral liquid efficiently for the treatment of anemopyretic cold.The present invention utilizes the hot pathogenic wind-heat that looses of Radix Bupleuri, reconciling superficies and interior, resolving depression soothing liver-QI; Be aided with Radix Scutellariae heat clearing and damp drying eliminating fire and detoxication, clearing heat secreting bile, two medicine mutual reinforcements between are usefulness, receive the merit of clearing away heat and expelling pathogen in the exterior altogether.Pharmacodynamics shows that the present invention can obviously reduce the hyperpyrexia that rabbit is caused by typhoid fever, paratyphoid vaccine, and the growth and breeding of can obviously rise and fall influenza A virus and Influenza B virus; Significantly alleviate mice ear, and can suppress the growth of rat agar granuloma, the antiinflammatory action that has all has the obvious suppression effect to alpha streptococcus, group B streptococcus etc.
Technical scheme of the present invention is based on motherland's medical science to pathogenic wind-warm diseases caused by exogenous pathogenic factor and merging pathogenetic understanding of symptom and Therapeutic Principle, achieve with reference to modern pharmacological research, from motherland's medical treasure-house, filter out the natural plants of relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, heat-clearing and toxic substances removing, according to the theory of Chinese medical science prescription.
Summary of the invention
The present invention seeks to be achieved through the following technical solutions
Medicine of the present invention is made by following component:
Fructus Forsythiae 300-500 weight portion Semen Sojae Preparatum 200-400 weight portion Herba Menthae 100-300 weight portion
Herba Schizonepetae 100-300 weight portion Fructus Gardeniae (stir-fry) 100-300 weight portion Radix Et Rhizoma Rhei 100-300 weight portion
Herba Artemisiae Annuae 200-400 weight portion Radix Paeoniae Rubra 100-300 weight portion Semen Arecae 100-300 weight portion
Cortex Magnoliae Officinalis 200-400 weight portion Radix Scutellariae 200-400 weight portion Rhizoma Pinelliae 200-400 weight portion
Radix Bupleuri 100-300 weight portion Radix Glycyrrhizae 100-300 weight portion
Medicine optimum weight part proportioning of the present invention is:
Fructus Forsythiae 444 weight portion Semen Sojae Preparatums 333 weight portion Herba Menthaes 222 weight portions
Herba Schizonepetae 222 weight portion Fructus Gardeniaes (stir-fry) 189 weight portion Radix Et Rhizoma Rhei 189 weight portions
Herba Artemisiae Annuae 333 weight portion Radix Paeoniae Rubra 222 weight portion Semen Arecaes 167 weight portions
The Cortex Magnoliae Officinalis 333 weight portion Radix Scutellariaes 333 weight portion Rhizoma Pinelliaes 333 weight portions
Radix Bupleuri 222 weight portion Radix Glycyrrhizaes 189 weight portions
Above crude drug can be made multiple dosage form as required, comprises oral liquid, tablet, capsule, granule, soft capsule and pill etc.These dosage forms are all refining through the extraction in early stage, and this process is as follows:
Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, and the aqueous solution after distillation device is in addition collected.Ten flavors such as all the other Semen Sojae Preparatums decoct with water 1-3 time with above-mentioned medicinal residues, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.02-1.15 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs, standing over night filters filtrate recycling ethanol, relative density is the thick paste of 1.25-1.40 when being concentrated into 55 ℃, and thick paste and volatile oil are added suitable adjuvant, makes required dosage form.
Technology after preferred is:
Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, volatile oil beta-schardinger dextrin-inclusion, and the aqueous solution after distillation device is in addition collected.Ten flavors such as all the other Semen Sojae Preparatums decoct with water secondary with above-mentioned medicinal residues, add 10 times of water gagings for the first time and decoct 1.5 hours, and 8 times of water gagings decocted 1 hour for the second time, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.05-1.10 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs, and standing over night filters, filtrate recycling ethanol, and relative density is the thick paste of 1.30-1.35 when being concentrated into 55 ℃.Get 2 parts of thick pastes, add 1 part of sucrose, 1 part in dextrin, sweeting agent is an amount of, vacuum drying, the beta-cyclo dextrin included compound mixing of pulverizing back and volatile oil is made granule.
This product can be used for treating infantile anemopyretic cold card, for determining drug effect, this product has been carried out pharmacodynamics test research, and particles used dose is optimal proportion and optimised process preparation and get according to the present invention in the test.Concrete test is as follows:
The specific embodiment:
Pharmaceutical preparation of the present invention has the function of dispelling wind to relieve the exterior syndrome, clearing away heat and resolving stagnation of food, and the inventor cures mainly according to its function, from cough-relieving, antibiosis its pharmacodynamics is verified.
The experiment of 1 antitussive action
1.1 drawing, Cavia porcellus ammonia coughs experiment
Get 50 of Cavia porcelluss, male and female half and half, body weight (200 ± 20) g is divided into 5 groups at random, and 10 every group, male and female half and half.Negative control group is irritated stomach and is given purified water, every 0.8mL; Positive controls gives pentoxyverine, and (trade name: carbetapentane citrate, Guizhou are also insulted pharmaceutical factory and are produced, lot number: H021215) medicine liquid irrigation stomach, 15mgkg
-1Experimental group 1,2,3 all irritate stomach gives the medicinal liquid that granule of the present invention is made, be respectively to contain the particulate amount of the present invention, 10,20gkg
-11h behind the gastric infusion places bell glass respectively with 5 groups of Cavia porcelluss, with ammonium hydroxide with the air pump equal pressure at the uniform velocity wind spray into 5s, observe the cough number of times that begins to occur respectively to organize in incubation period of cough and the 3min Cavia porcellus from spraying to Cavia porcellus.
1.2 drawing, cat electricity irritation superior laryngeal nerve coughs experiment
Get 30 of cats, male and female half and half, body weight (2.5 ± 0.5) kg is divided into 5 groups at random, i.e. feminine gender, positive controls and experimental group 1,2,3.After the grouping cat given chloralose (with the dissolving of propylene glycerol) intraperitoneal injection of anesthesia, 80mgkg
-1Then cat is fixed on the operating-table with back of the body formula, cuts skin, separate subcutaneous tissue and superior laryngeal nerve, shield electrode is contacted with superior laryngeal nerve, paraffin is coated in neural and electrode contact site fixed electrode, in order to stimulating along the neck median line.Hara kiri skin, the expose portion rectus abdominis m. is fixed in rectus abdominis m. with silk thread one end, and the other end is connected in transducer, during the cat cough, the movable traction of diaphram rectus abdominis m., physiograph just can write down the number of times and the intensity of its cough.The femoral vein that separates the positive controls cat is so that administration.Each treated animal (before administration) after operation is finished begins to stimulate superior laryngeal nerve, and the electricity irritation of determining every cat is drawn and coughed threshold value.Electricity irritation condition: JL2C4 type physiological stimulation instrument, stimulus frequency 50Hz, pulse width 0.5ms.Continued stimulus 5s, twice stimulus intervals time is 3min, and stimulation voltage is progressively increased progressively to big by little, and every side superior laryngeal nerve occurs coughing in continuous 5s magnitude of voltage is the cough threshold value of this cat.After having surveyed the cough threshold value of every cat, experimental group 1,2,3 all give the medicine liquid irrigation stomach that granule of the present invention is made with intubation of esophagus, are respectively 5,10,20gkg by the particulate amount of the present invention
-1Negative control group gives 0.9% sodium chloride injection, every 5mL; Positive controls gives Codeine Hydrochloride vena femoralis injection, 3mgkg
-1Measure cough threshold value 1 time every 30min after the administration, observe time, action intensity (threshold value) that medicine continues each group cat antitussive effect.
The experiment of 2 antibacterial actions
2.1 the mensuration of pathogenic bacterium minimum lethal dose (MLD)
With " 1.1 " down preparation bacterium liquid to be diluted to concentration successively with 0.9% sodium chloride injection be 1.0 * 10
-1, 1.0 * 10
-2, 1.0 * 10
-3, 1.0 * 10
-4GL
-1Bacterium liquid standby.Get 40 of Kunming mouses, body weight (20 ± 1) g, male and female half and half are divided into 4 groups at random, and 10 every group, male and female half and half.Experimental group 1,2,3,4 mouse peritoneals injection concentration successively are 1 * 10
-1, 1 * 10
-2, 1 * 10
-3With 1 * 10
-4GL
-1Bacterium liquid.Observe in the 7d of inoculation back and respectively organize the dead mouse number.The results are shown in Table 1.As seen, streptococcus pneumoniae is 1 * 10 to the MLD of mice from table 1
-1GL
-1
Table 1 streptococcus pneumoniae is to the MLD of mice
| To bacterium amount/(gL21) | Number of animals/only | Death toll/only | Mortality rate/% |
| 1×10 -1 | 10 | 10 | 100 |
| 1×10 -2 | 10 | 7 | 70 |
| 1×10 -3 | 10 | 2 | 20 |
| 1×10 -4 | 10 | 0 | 0 |
2.2 granule of the present invention is to the protective effect of pneumococcal infection mice
50 of Kunming mouses are got in experiment, and male, body weight (20 ± 1) g is divided into 5 groups at random, i.e. negative control group, positive controls and experimental group 1,2,3.Experimental group 1,2,3 irritate stomach respectively gives the medicinal liquid that granule of the present invention is made, and in crude drug of the present invention, dosage is respectively 5,10,20gkg
-1Positive controls lumbar injection streptomycin, dosage 1.0mgkg
-1Negative control group does not give any medicine.Each organizes mice, and 1h is with above-mentioned dosed administration 1 time before the injection streptococcus pneumoniae, and every group of standby concentration of mouse peritoneal inoculated and cultured is 1 * 10 subsequently
-2GL
-1Streptococcus pneumoniae, 0.02mLg
-1Behind the injection strain 1,6, each group of 12h is above dosed administration 1 time respectively.Observe in the 5d and respectively organize the dead mouse situation.
3 results
3.1 the antitussive action to Cavia porcellus the results are shown in Table 2.As shown in Table 2, compare with negative control group, obviously prolong the incubation period of experimental group 3 and positive controls Cavia porcellus, and the cough number of times significantly reduces, and all difference has utmost point significance (all P＜0.01); Also prolong the incubation period of experimental group 2 Cavia porcelluss, and the cough number of times also obviously reduces (all P＜0.05), prompting high dose (20gkg
-1) granule prolonged guinea pig cough latent period of the present invention is suitable with the effect and the pentoxyverine of guinea pig cough's number of times of reducing, and this effect is dose dependent, the particulate antitussive action of high dose the present invention is more obvious.
3.2 the antitussive action to cat the results are shown in Table 3.As shown in Table 3, give granule of the present invention after, experimental group 1,2,3 cats are drawn and cough before threshold value and the administration relatively, and obvious rising is all arranged.With negative control group relatively, experimental group 2 and 3 significantly raises, and this effect is dose dependent, along with dosage raises, drug treating time is prolongation thereupon also.Granule 20gkg of the present invention
-1With Codeine Hydrochloride 3mgkg
-1Antitussive action suitable.
Table 2 granule of the present invention is to antitussive action x ± s of Cavia porcellus, n=6
| Group | Incubation period/s | The cough number of times/time |
| Experimental group 1 | 84.5±19.3 | 21.3±7.1 |
| Experimental group 2 | 90.6±14.6 | 15.6±5.4 *1 |
| Experimental group 3 | 113.4±17.9 | 9.8±5.9 *2 |
| Positive controls | 121.6±26.7 | 18.4±17.8 *3 |
| Negative control group | 59.3±8.5 | 24.7±7.1 |
Annotate: compare with negative control group,
* 1P＜0.05;
* 2P＜0.01
Table 3 granule of the present invention draws the V that influences that coughs threshold value, x ± s, n=6 to cat
| Group | Threshold value before the administration | Threshold value after the administration | |||||
| 30min | 60min | 90min | 120min | 150min | 180min | ||
| Experimental group 1 | 7.1±1.3 | 7.4±2.3 | 8.2±1.3 | 8.7±2.4 | 8.4±2.2 | 7.2±2.6 | 6.3±1.2 |
| Experimental group 2 | 6.7±1.2 | 7.3±2.2 | 11.4±2.1 | 12.4±3.5 *1 | 14.4±2.4 *1 | 14.4±3.4 *1 | 10.8±2.7 *2 |
| Experimental group 3 | 7.1±1.5 | 9.3±2.2 *2 | 13.4±3.5 *1 | 13.5±3.1 *1 | 14.3±3.1 *1 | 15.3±3.6 *1 | 13.5±2.6 *2 |
| Positive controls | 6.4±1.8 | 16.2±3.1 *1 | 14.4±2.3 *1 | 12.7±2.4 *1 | 14.4±3.6 *1 | 14.6±2.4 *2 | 9.3±1.7 |
| Negative control group | 6.4±1.5 | 6.2±1.3 | 6.2±2.7 | 6.9±1.4 | 5.7±1.8 | 6.7±2.4 | 5.9±2.5 |
Annotate: compare with negative control group,
* 1P＜0.01;
* 2P＜0.05
3.3 granule of the present invention the results are shown in Table 4 to the protective effect of pneumococcal infection mice.As shown in Table 4, granule of the present invention has significant protective effect to the mice of pneumonia infection coccus, and drug effect increases along with the increase of dosage, but granule 20gkg of the present invention
-1Curative effect still than streptomycin 1.0gkg
-1Curative effect low.
Table 4 granule of the present invention is to the protective effect of pneumonia infection coccus mice
| Group | The experiment mice number | Survival number in the 5d |
| Experimental group 1 | 10 | 1 |
| Experimental group 2 | 10 | 4 *1 |
| Experimental group 3 | 10 | 7 *2 |
| Positive controls | 10 | 10 *2 |
| Negative control group | 10 | 0 |
Annotate: compare with negative control group,
* 1P＜0.01;
* 2P＜0.05
By experiment as can be known, give high dose granule of the present invention and can obviously prolong the animal cough latent period, and the cough number of times reduces with the dosage increase.Results suggest granule dosage＞10gkg of the present invention
-1The time antitussive action arranged.And mice is attacked in the streptococcus pneumoniae abdominal cavity certain therapeutical effect is arranged.Be that we have tangible antitussive action, and the mice of pneumonia infection coccus is had significant protective effect.
Below further specify technical scheme of the present invention with the specific embodiment, but the claimed scope of the application is not limited in dosage form described in the embodiment.
The specific embodiment:
Embodiment 1
[prescription] Fructus Forsythiae 444g Semen Sojae Preparatum 333g Herba Menthae 222g Herba Schizonepetae 222g
Fructus Gardeniae (stir-fry) 189g Radix Et Rhizoma Rhei 189g Herba Artemisiae Annuae 333g Radix Paeoniae Rubra 222g
Semen Arecae 167g Cortex Magnoliae Officinalis 333g Radix Scutellariae 333g Rhizoma Pinelliae 333g
Radix Bupleuri 222g Radix Glycyrrhizae 189g
[method for making] Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, volatile oil beta-schardinger dextrin-inclusion, and the aqueous solution after distillation device is in addition collected.Ten flavors such as all the other Semen Sojae Preparatums decoct with water secondary with above-mentioned medicinal residues, add 10 times of water gagings for the first time and decoct 1.5 hours, and 8 times of water gagings decocted 1 hour for the second time, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.05-1.10 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs, and standing over night filters, filtrate recycling ethanol, and relative density is the thick paste of 1.30-1.35 when being concentrated into 55 ℃.Get 2 parts of thick pastes, add 1 part of sucrose, 1 part in dextrin, sweeting agent is an amount of, and the beta-cyclo dextrin included compound mixing of volatile oil is made granule, and drying is made 1000g, packing, promptly.
Embodiment 2
[prescription] Fructus Forsythiae 444g Semen Sojae Preparatum 333g Herba Menthae 222g Herba Schizonepetae 222g
Fructus Gardeniae (stir-fry) 189g Radix Et Rhizoma Rhei 189g Herba Artemisiae Annuae 333g Radix Paeoniae Rubra 222g
Semen Arecae 167g Cortex Magnoliae Officinalis 333g Radix Scutellariae 333g Rhizoma Pinelliae 333g
Radix Bupleuri 222g Radix Glycyrrhizae 189g
[method for making] Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, and the aqueous solution after distillation device is in addition collected.Ten flavors such as all the other Semen Sojae Preparatums decoct with water secondary with above-mentioned medicinal residues, add 10 times of water gagings for the first time and decoct 1.5 hours, and 8 times of water gagings decocted 1 hour for the second time, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.05-1.10 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs standing over night, filter, filtrate recycling ethanol, relative density is 1.10-1.15 when being concentrated into 55 ℃, adding volatile oil and sucrose are an amount of, make 1000ml, packing, sterilization, promptly.
Claims (6)
1, a kind of Chinese medicine composition is characterized in that this Chinese medicine composition is to be made by following raw medicaments in portion by weight:
Fructus Forsythiae 300-500 weight portion Semen Sojae Preparatum 200-400 weight portion Herba Menthae 100-300 weight portion
Herba Schizonepetae 100-300 weight portion Fructus Gardeniae 100-300 weight portion Radix Et Rhizoma Rhei 100-300 weight portion
Herba Artemisiae Annuae 200-400 weight portion Radix Paeoniae Rubra 100-300 weight portion Semen Arecae 100-300 weight portion
Cortex Magnoliae Officinalis 200-400 weight portion Radix Scutellariae 200-400 weight portion Rhizoma Pinelliae 200-400 weight portion
Radix Bupleuri 100-300 weight portion Radix Glycyrrhizae 100-300 weight portion.
2, Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition is to be made by following raw material medicaments:
Fructus Forsythiae 444 weight portion Semen Sojae Preparatums 333 weight portion Herba Menthaes 222 weight portions
Herba Schizonepetae 222 weight portion Fructus Gardeniaes 189 weight portion Radix Et Rhizoma Rhei 189 weight portions
Herba Artemisiae Annuae 333 weight portion Radix Paeoniae Rubra 222 weight portion Semen Arecaes 167 weight portions
The Cortex Magnoliae Officinalis 333 weight portion Radix Scutellariaes 333 weight portion Rhizoma Pinelliaes 333 weight portions
Radix Bupleuri 222 weight portion Radix Glycyrrhizaes 189 weight portions.
3, Chinese medicine composition as claimed in claim 1 or 2 is characterized in that making multiple regular dosage form, comprises clinical common formulations such as tablet, capsule, granule, soft capsule and pill.
4, preparation of drug combination method as claimed in claim 3 is characterized in that passing through following steps: Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, and the aqueous solution after distillation device is in addition collected.Ten flavors such as all the other Semen Sojae Preparatums decoct with water 1-3 time with above-mentioned medicinal residues, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.02-1.15 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs, standing over night filters filtrate recycling ethanol, relative density is the thick paste of 1.25-1.40 when being concentrated into 55 ℃, and thick paste and volatile oil are added suitable adjuvant, makes required dosage form.
5, as the preparation method of Chinese medicine composition as described in the claim 4, it is characterized in that this method is: Fructus Forsythiae, Herba Menthae, Herba Schizonepetae, Radix Bupleuri four flavors extract volatile oil, volatile oil beta-schardinger dextrin-inclusion, the device collection in addition of the aqueous solution after the distillation.Ten flavors such as all the other Semen Sojae Preparatums decoct with water secondary with above-mentioned medicinal residues, add 10 times of water gagings for the first time and decoct 1.5 hours, and 8 times of water gagings decocted 1 hour for the second time, and collecting decoction filters, and filtrate and above-mentioned aqueous solution merge.Relative density is the clear paste of 1.05-1.10 during solution concentration to 55 ℃, adds ethanol and makes ethanol content reach 65%, stirs, and standing over night filters, filtrate recycling ethanol, and relative density is the thick paste of 1.30-1.35 when being concentrated into 55 ℃.Get 2 parts of thick pastes, add 1 part of sucrose, 1 part in dextrin, sweeting agent is an amount of, vacuum drying, the beta-cyclo dextrin included compound mixing of pulverizing back and volatile oil is made granule.
6, the application of Chinese medicine composition in the medicine of preparation treatment infantile anemopyretic cold as claimed in claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510105972 CN1943689A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510105972 CN1943689A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1943689A true CN1943689A (en) | 2007-04-11 |
Family
ID=38043483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510105972 Pending CN1943689A (en) | 2005-10-08 | 2005-10-08 | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1943689A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234139B (en) * | 2008-02-28 | 2011-09-07 | 美晨集团股份有限公司 | Proprietary Chinese medicine for curing common cold and preparation thereof |
| CN102579846A (en) * | 2012-03-09 | 2012-07-18 | 广西强寿药业集团有限公司 | Chinese patent medicament wind-calming and pain-relieving granules for treating migraine and preparation method thereof |
| CN102793876A (en) * | 2012-09-05 | 2012-11-28 | 成都中医药大学 | Pharmaceutical composition for treating fever caused by unknown reason as well as preparation method and application of pharmaceutical composition |
| CN104116781A (en) * | 2014-07-31 | 2014-10-29 | 河南科技大学第一附属医院 | Oral liquid for treating cold and preparation method of oral liquid |
| CN104127490A (en) * | 2014-07-31 | 2014-11-05 | 河南科技大学第一附属医院 | Cold oral liquid and preparation method thereof |
| CN104257927A (en) * | 2014-10-16 | 2015-01-07 | 徐艳 | Common goldenrop soft capsule for treating anemopyretic cold as well as preparation method and application of soft capsule |
| CN106806710A (en) * | 2016-11-28 | 2017-06-09 | 李元英 | A kind of traditional Chinese powder medicine for treating cough due to wind-heat evil |
| CN106924448A (en) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof |
| CN109223930A (en) * | 2018-10-19 | 2019-01-18 | 济川药业集团有限公司 | A kind of medical syrup and preparation method thereof for treating children's wind-heat cold |
| CN110898176A (en) * | 2019-12-06 | 2020-03-24 | 冼启福 | Traditional Chinese medicine composition for treating cold |
| CN112386646A (en) * | 2019-08-13 | 2021-02-23 | 济川药业集团有限公司 | Pharmaceutical composition and preparation method and application thereof |
-
2005
- 2005-10-08 CN CN 200510105972 patent/CN1943689A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234139B (en) * | 2008-02-28 | 2011-09-07 | 美晨集团股份有限公司 | Proprietary Chinese medicine for curing common cold and preparation thereof |
| CN102579846A (en) * | 2012-03-09 | 2012-07-18 | 广西强寿药业集团有限公司 | Chinese patent medicament wind-calming and pain-relieving granules for treating migraine and preparation method thereof |
| CN102793876A (en) * | 2012-09-05 | 2012-11-28 | 成都中医药大学 | Pharmaceutical composition for treating fever caused by unknown reason as well as preparation method and application of pharmaceutical composition |
| CN104116781A (en) * | 2014-07-31 | 2014-10-29 | 河南科技大学第一附属医院 | Oral liquid for treating cold and preparation method of oral liquid |
| CN104127490A (en) * | 2014-07-31 | 2014-11-05 | 河南科技大学第一附属医院 | Cold oral liquid and preparation method thereof |
| CN104257927A (en) * | 2014-10-16 | 2015-01-07 | 徐艳 | Common goldenrop soft capsule for treating anemopyretic cold as well as preparation method and application of soft capsule |
| CN106806710A (en) * | 2016-11-28 | 2017-06-09 | 李元英 | A kind of traditional Chinese powder medicine for treating cough due to wind-heat evil |
| CN106924448A (en) * | 2017-01-10 | 2017-07-07 | 湖南华纳大药厂天然药物有限公司 | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof |
| CN106924448B (en) * | 2017-01-10 | 2020-04-24 | 湖南华纳大药厂天然药物有限公司 | Pharmaceutical composition for treating wind-heat type common cold and preparation method thereof |
| CN109223930A (en) * | 2018-10-19 | 2019-01-18 | 济川药业集团有限公司 | A kind of medical syrup and preparation method thereof for treating children's wind-heat cold |
| CN109223930B (en) * | 2018-10-19 | 2021-08-03 | 济川药业集团有限公司 | Medicinal syrup for treating wind-heat type common cold of children and preparation method thereof |
| CN112386646A (en) * | 2019-08-13 | 2021-02-23 | 济川药业集团有限公司 | Pharmaceutical composition and preparation method and application thereof |
| CN112386646B (en) * | 2019-08-13 | 2022-04-12 | 济川药业集团有限公司 | A kind of pharmaceutical composition and its preparation method and application |
| CN110898176A (en) * | 2019-12-06 | 2020-03-24 | 冼启福 | Traditional Chinese medicine composition for treating cold |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1943689A (en) | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method | |
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN1054773C (en) | Chinese patent drug "Bizhengning" for treatment of arthralgia-syndrome | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN1679864A (en) | Chinese medicine preparation for treating bronchitis | |
| CN1954866A (en) | Medicine for treating odontopathy and its preparation method | |
| CN1053363C (en) | Oral liquid of shengxueyin | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1686501A (en) | Compound Chinese medicine for treating child diarrhea and its preparation method | |
| CN1289124C (en) | Medicine for treating child common cold and its preparation method | |
| CN1931277A (en) | Osteoarthrosis treating Chinese medicine composition and its prepn process | |
| CN111514230A (en) | Lung-ventilating and lung-ventilating traditional Chinese medicine capsule containing ephedra and apricot seeds and preparation method of lung-ventilating and lung-ventilating traditional Chinese medicine capsule | |
| CN116570664B (en) | A Chinese medicine composition for treating chicken leg arthritis and its application | |
| CN1958008A (en) | Animal use compound medicament with effects of removing toxic heat, and preparation method | |
| CN1352966A (en) | Medicine for treating tracheitis and asthma | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN1958023A (en) | Animal use compound medicament with effects for invigorating qi, strengthening the superficial, dispelling wind-evil, and being sensible, and preparation method | |
| CN1424104A (en) | Medicines for treating chronic prostatitis and preparation thereof | |
| CN110025685B (en) | A liquid preparation containing propolis composition | |
| CN1579434A (en) | Chaihuang Tonic and its preparation method | |
| CN1954877A (en) | Chinese medicinal composite for treating ischemic necrosis of femoral head and its preparation method | |
| CN1631389A (en) | Medicine for treating acute and chronic pharyngitis and its preparing process | |
| CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |